Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Katairo GmbH: patented active substance to combat previously incurable eye disease
Ray of hope for millions of patients

(Stuttgart/Kusterdingen/Frankfurt am Main) – The 2012 Innovation Award of the biotechnology regions in Germany was presented to Prof. Ulrich Schraermeyer on 9 May 2012 in Frankfurt am Main. The Tübingen-based researcher received the award in recognition of his idea to use an active substance to treat the dry form of age-related macular degeneration (AMD). This impedes a patient’s ability to see and can ultimately lead to complete blindness. In the interest of those affected by the disease, Prof. Schraermeyer founded Katairo GmbH to enable him to patent and market his findings as quickly as possible.

In Germany alone, around 4.5 million people suffer from the dry form of age-related macular degeneration, the most common cause of blindness in the industrialised world. Up to now, dry AMD has been considered untreatable. However, Prof. Ulrich Schraermeyer, head of the Experimental Vitreoretinal Surgery section at the University Eye Clinic Tübingen, has published groundbreaking research results that could enable successful treatment in a few years’ time.

Prof. Schraermeyer is an expert in the pathology of the retinal pigment epithelium, the layer of cells in the eye that is affected by the pathological changes associated with AMD. Decades of toxic lipofuscin consisting of metabolites that cannot be excreted by the cells can accumulate in this layer, causing the photoreceptors in the retina to die. Prof. Schraermeyer has now discovered that a specific active substance can help break down most of the lipofuscin, thus enabling it to be excreted.

It is not only scientists who are excited by this discovery. Shortly after the findings were published in a medical journal, the first investors from the United States had already shown interest. Prof. Schraermeyer recognises the significance of his findings. He therefore founded Katairo GmbH, based in Kusterdingen near Tübingen, to enable him to patent and market the active substance. “Potential investors need a company to invest in”, explains Prof. Schraermeyer. The fact that the active substance has already been developed to clinical phase II by a pharmaceutical company – for a completely different application – also makes the discovery interesting for investors. This means that the active substance stands an excellent chance of receiving fast approval for clinical phase I treatment of dry AMD. “Because the medical need is great and there has been no treatment whatsoever to date, the likelihood of financing through venture capital or the pharmaceutical industry is very high”, says Prof. Schraermeyer. “I estimate that around five million euros would be sufficient to carry out a phase I study for the treatment of dry AMD.”

Prof. Schraermeyer received the Innovation Award of the biotechnology regions in Germany on 9 May 2012 in Frankfurt am Main. The award is in recognition of his idea, which has resulted in the discovery of a treatment for the causes of dry AMD. The panel of experts all agreed that this project from the STERN BioRegion is a prime example of excellent basic research coupled with economic feasibility.

About BioRegio STERN:
For ten years, BioRegio STERN Management GmbH has been a skill-sharing network in the cities of Stuttgart, Tübingen, Esslingen, and Reutlingen and the Neckar-Alb and Stuttgart regions in the Baden-Württemberg area of Germany, providing a source of help and advice for founders of new businesses, entrepreneurs and researchers from the biotechnology sector. BioRegio STERN Management GmbH represents their interests in dealings with politicians, the media and associations. It offers business promotion and marketing services and provides advice on grant applications and corporate financing. Regenerative medicine, medical technology and the automation of biotechnology are key focal points. The Managing Director, Dr. Klaus Eichenberg, is a molecular and cell biologist and investment analyst.

About Katairo:
Katairo GmbH was founded by Prof. Ulrich Schraermeyer and three other partners in 2011. The company, based in Kusterdingen near Tübingen, enables the patenting and marketing of THPE, an active substance for the effective treatment of the dry form of age-related macular degeneration (AMD).

Publisher: BioRegio STERN Management GmbH
Friedrichstrasse 10, 70174 Stuttgart, Germany, +49-711-8703540,
Editor: Zeeb Kommunikation GmbH,
Hohenheimer Strasse 58a, 70184 Stuttgart, Germany, +49-711-6070719,
Prof. Ulrich Schraermeyer, University of Tübingen, Section Head, +49-7071-2980715,

Publisher Contact Information:

University of Tübingen

Company profile of BioRegio STERN Management
Past press releases of BioRegio STERN Management.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.